Impact of Cangrelor on Outcomes After Percutaneous Coronary Intervention for Acute Coronary Syndrome in High Bleeding Risk Patients. (PubMed, Am J Cardiol) - Mar 2, 2026 - "Multivariate analysis adjusting for age, STE-ACS, new onset CHF, and AKI showed similar ischemic [OR(CI): 1.52(0.68-3.27), p=0.30] and major bleeding [OR(CI): 1.65(0.92-2.93), p=0.09] outcomes among cangrelor and non-cangrelor patients. In conclusion, cangrelor use in HBR ACS patients undergoing PCI was not associated with improved outcomes versus oral P2Y12 inhibitors, although similar event rates despite higher acuity in the cangrelor group may suggest potential benefit in select patients without added bleeding risk."
Journal • Acute Coronary Syndrome • Acute Kidney Injury • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Congestive Heart Failure • Heart Failure • Hematological Disorders • Ischemic stroke • Nephrology • Renal Disease • Thrombosis
|
|
Abhishek Chaturvedi; Andrew P Hill; Brian C Case; Cheng Zhang; Dan Haberman; Hank Rappaport; Hayder D Hashim; Itsik Ben-Dor; Lior Lupu; Lowell F Satler; Matteo Cellamare; Patrick J Creechan; Ron Waksman; Toby Rogers; Vaishnavi Sawant; Waiel Abusnina
|